Last reviewed · How we verify
NCT06999824: Neuro-Nerve
Revisiting the Concept of Nerve Sparing Radical Hysterectomy
trial in Cervical Cancers in 15 participants. Not yet recruiting.
1 March 2026
Quick facts
| Lead sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 1 June 2025 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 May 2027 |
| Sites | 1 location across Italy |
Conditions studied
- Cervical Cancers — all drugs for Cervical Cancers →
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — full company profile →
Who can join
18 and older, female only, with Cervical Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nerve-sparing radical hysterectomy aims to preserve the autonomic innervation of pelvic organs. In most studies, the preservation of the parasympathetic component of pelvic innervation is achieved by sparing the lymphovascular-neural tissue located at the base of the lateral paracervical tissue. This study explores an alternative surgical technique based on a different anatomical pathway of parasympathetic fibers, running more cranially and deeply within the pararectal space.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06999824
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancers
Currently open trials in the same condition.
- NCT06910657 — IDOV-Immune for Advanced Solid Tumors · Phase 1 · recruiting
- NCT07130240 — Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 a · Phase 2 · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT06867445 — Minimally Invasive Pelvic Exenteration in Vaginal or Cervical Cancer Recurrence · NA · recruiting
- NCT07003620 — Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial · Phase 2 · recruiting
Other Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials
Trials by the same sponsor.
- NCT06799624 — Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr · not yet recruiting
- NCT07253402 — Microbiota-guided Radiotherapy for Head and Neck Cancer · recruiting
- NCT06938724 — Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer · Phase 2 · recruiting
- NCT06986486 — Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma · recruiting
- NCT06862934 — Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06999824 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Last refreshed: 31 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06999824.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing